Partners: Lucence Health, CCTH

Summary: Liquid Biopsy for Detection of Actionable Genomic Mutations in Women of African Descent with Advanced Breast Cancer, also known as the AMBER Study– is a prospective, observational trial exploring the utility of a cfDNA liquid biopsy assay to identify actionable genetic mutations in metastatic breast cancer patients in Ghana. Using Lucence’s LiquidHALLMARK® assay, the study will examine actionable mutations in genes including PIK3CA, BRCA1, BRCA2, and ESR1 in treatment-naive metastatic breast cancer patients recruited from Cape Coast Teaching Hospital with the goal of identifying and evaluating the mutation profiles of cancers in Ghanaian women.